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The increase in the detection of small renal masses (SRMs) and their best knowledge leads to a change in the therapeutic
managementoftheselesions.Theuseofalessaggressivesurgicaltechniqueorevenanexpectantattitudeisthecurrenttendency,in
order to preserve as much renal function as possible. Imaging techniques are essential in the followup of these lesions. It allows us
toknowthepostsurgicalchanges and possiblecomplications duetotreatment and thepresence oflocal recurrenceand metastases.
Furthermore, a close radiological followup of SRM related to ablative treatments is mandatory. The purpose of this article is to
reveal the imaging features of complications due to surgical or ablative treatments, local recurrence and metastasis, as well as their
followup.
Copyright © 2008 J. Santos et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. IMAGING FOLLOWUP OF SRM
Severalauthorshavereportedthatsmallincidentallydetected
tumors are associated with better survival outcomes. The
5-year disease-free survival rate for incidental renal tumors
of <4cm treated with radical or partial nephrectomy is
95%–100%. There is a clear increased rate of metastases in
patients found to have renal cell carcinoma (RCC) >3cm
in maximum dimension at autopsy compared to those with
RCCs of < or =3cm[1, 2].
Silverman et al. [3] have established the indications
for percutaneous biopsy of renal masses in patients with
a renal mass and known extrarenal primary malignancy,
imaging ﬁndings that suggest unresectable renal cancer,
surgical comorbidity, those that may have been caused by
an infection. Emerging indications are patients with a small
(<3cm) hyperattenuating, homogeneusly enhancing renal
mass, those with a renal mass considered for percutaneus
ablation and patients with an indeterminate cystic renal
mass.
After surgical treatment, radical nephrectomy (RN) or
partial nephrectomy (PN), about 20%–30% of patients with
localized renal tumors relapse [4]. The recurrences occur
three years after surgery, with a median time to relapse
being 1 to 2 years. In multifocal renal cortical tumors, local
recurrences rates following elective partial nephectomy are
from 0% to 10% with a risk of local recurrence for tumors of
4cmorless[5]. However, late tumor recurrences can occur
many years after treatment. The lung is the most vulnerable
site for distant recurrence (50%–60% of patients) [6]. Other
sites of recurrence are bone, surgical site, brain, liver, and the
contralateral kidney.
There are multiple prognostic factors to predict recur-
rence after surgery. A postoperative prognostic nomogram
has been published predicting recurrence for patients with
conventional clear cell renal cell carcinoma [7], and it can
be useful for patient counselling, clinical trial, and eﬀective
patient followup strategies.
Greatest tumor diameter, T stage, stage group, and
nuclear grade are important factors in determining the like-
lihood of recurrence. At the present time, active surveillance
of small renal masses is an experimental approach, but
represents an attractive option for elderly patients and those
with signiﬁcant comorbidity.
Bilateral multifocal renal tumors are present in approx-
imately 5% of patients with sporadic renal tumors [8].
Conventional clear cell carcinoma is the most common
histologic subtype, followed by papillary carcinoma [5].
Most of them can be synchronous but asynchronous
lesions may occur many years after the initial nephrec-
tomy, and that is why a long-term followup. must be
maintained.2 Advances in Urology
In imaging followup evaluation of kidney cancer, CT
is the modality of choice for detection of local recurrence
and distant metastases. In patients with compromised renal
function or with contraindications to iodinated contrast,
gadolinium-enhanced MR imaging of the abdomen and
pelvismaybeused.AlsoachestradiographorchestCTstudy
can be performed for surveillance of pulmonary metastasis.
Renal cysts are common benign lesions and are often an
incidental ﬁnding during abdominal CT, (see the appendix)
[9]. If they are of ﬂuid attenuation, lack internal architecture,
have thin walls, and show no evidence of enhancement after
IV contrast administration, they can be easily dismissed as
benign. However, the appearance of moderately complex or
mild renal cyst varies and can cause diﬃculties in diagnosis
and management. The Bosniak classiﬁcation or renal cysts
has proven to be a useful tool in helping to evaluate
these lesions and decide clinical management [10]. In 1993,
Bosniak revised the original classiﬁcation system [11]t o
include a subset of category II lesions, category IIF lesions
(“F” for followup).
CT studies arean eﬀective wayofmanaging patients with
moderately complex cystic lesions of the kidney (Bosniak
category IIF) because the absence of change supports
benignity and progression indicates neoplasm. Alternatively,
MRI may prove helpful in the characterization of these
lesions and may possibly avoid the need for followup
examinations in these cases [12]. In these lesions considered
to be category IIF, the followup examinations are necessary
to prove stability and, therefore,benignity. Theﬁrstfollowup
examination is recommended 6 months after the initial
examination. If the lesion is unchanged, additional followup
examinations should be performed at yearly intervals for at
least 5 years, although the optimal followup period has not
been determined. However, in younger patients, a longer
followup period may be necessary.
45% of the patients with von Hippel-Lindau disease
will have a renal adenocarcinoma, often (80%) multifocal
or bilateral. Treatment must be as conservative as possible
because of the multifocality and its usual low grade. The risk
of recidive is very high: 30% at 5 years, 80% at 10 years,
therefore, they must be followed up strictly and regularly
(Figure 1)[ 13].
2. IMAGING OF COMPLICATIONS OF
PARTIAL NEPHRECTOMY
The standard treatment for renal cell carcinoma was, for
many years, radical nephrectomy, but over the past 10 years,
there has been a trend toward the use of nephron-sparing
surgerytotreatrenalcellcarcinoma.Theresultsofnumerous
studies have demonstrated equivalent cancer survival rates
for patients who underwent radical nephrectomy and those
who underwent partial nephrectomy for small renal neo-
plasms [14–16].
The procedure can be performed by using open or
laparoscopic techniques. However, partial nephrectomy with
laparoscopic techniques is a more complex operation than
the traditional radical nephrectomy and higher complication
rates have been reported [17].
(a)
(b)
(c)
Figure 1: 37-year old woman with von Hipple Lindau disease.
Radical right nefrectomy and partial tumorectomy in left kidney.
(a) Axial contrast-enhanced CT scan shows scar in the lower
pole in the left kidney (arrow), without any mass. Note the
absence of right kidney. (b) One year later sagittal US scan with
a large mass less echogenic than renal sinus fat, involving the
lower pole parenchyma (arrows). (c) Axial contrast-enhanced CT
(nephrographic phase) scan obtained at the same time shows the
mass that has grown with perinephric extension (white arrow). It
was a renal adenocarcinoma. Note of the presence of paraaorthic
lymph node (black arrow).
It is important to know normal ﬁndings and imaging
features of postsurgical complications after partial nephrec-
tomy, for appropriate postoperative management.
2.1. Postoperativeappearance
The appearance of the postoperative kidney depends on
the size and location of the resected tumor. After partial
nephrectomy for a small peripheral tumor, a wedge-shaped
defect in the renal parenchyma is typically visible at CT and
MR imaging. The postoperative kidney usually has a more
posterior location and abuts to the posterior abdominal wall
(Figure 2). Perinephric fat maybe packed into the surgical
bed to help achieve haemostasis. This material may be
mistaken for a fatty mass such as an AML.J. Santos et al. 3
Figure 2: Postoperative ﬁndings after laparoscopic left partial
nephrectomy, image shows a posterior location of the left kidney,
which abuts the posterior abdominal wall.
To help control intraoperative bleeding, biologically
absorbable haemostatic agents also may be used. Such mate-
rials may contain bubbles or air pockets that may resemble
a focal abscess. The possible presence of a haemostatic agent
should be considered if a linear arrangement of air bubbles
is noted or if air bubbles maintain the same position on
subsequent images. In most cases, the air in a haemostatic
agentisrapidlyreabsorbedduringtheﬁrstpostsurgicalweek.
However, in some cases, air bubbles can be identiﬁed on
images even 1 month after surgery. The presence of an
abscess should be suspected if a localized ﬂuid collection
that has an enhanced rim and contains gas bubbles or a
gas-ﬂuid level is seen. In addition, decreased intensity of
the nephrogram because of edema in the surrounding renal
parenchymasupportsthediagnosisofanabscess.Ofcourseit
is necessary to consider the imaging ﬁndings in combination
with the patient’s clinical history and symptoms [18–20].
The biologically absorbable haemostatic agents may also
mimic a pseudotumor that can lead to confusion. Several
cases have been reported on literature after nephron-sparing
surgeryusinggelatinebioabsorbablesponge.Theywereseen
as solid masses, with regular borders and enhancement after
injection of intravenous contrast agent, due to the presence
on granulomatous tissue surrounding the haemostatic mate-
rial. In all the cases there was a complete resolution of such
lesions in an average time of thirteen months [21, 22].
2.2. Complications
Complications seen on partial nephrectomy can be divided
into vascular complications, complications in the collecting
system, infection, recurrent tumor and complications due to
technical factors [20].
2.2.1. Vascularcomplications
During partial nephrectomy, the renal hiliar vessels must
be temporarily clamped to ensure a bloodless surgical ﬁeld;
however, clamping may injure the arterial intima and lead to
thrombosis.Ifthatcomplicationisnotrecognizedatthetime
Figure 3: Hematoma after open right partial nephrectomy. Mass
with attenuation of 60HU that extends from postoperative bed to
the perinephric space.
of surgery or in the immediate postoperative period, renal
infarction and atrophy will occur. Complications related to
injury of the intrarenal arteries in the surgical bed may also
occur. A hematoma may result if the suturing of transected
blood vessels is inadequate (Figure 3). A pseudoaneurysm
may result from injury to an intrarenal artery at the surgical
site or to the main renal artery or one of its major branches
[23–25].
2.2.2. Complicationsinthecollectingsystem
Whencalycealentryisnecessary,itwouldhavetoberepaired
in order to avoid urinary leakage. If the repair is not
watertight, a urine leak may occur into the surgical bed.
Such leakage may have the appearance of a simple ﬂuid
collection in the perirenal space [26], or it may have a more
heterogeneousappearanceifitcontainsbloodproducts.This
complication can be diagnosed on the basis of contrast-
enhanced CT and MR images acquired during the excretory
phase,withtheobservationofcontrastmaterialleakagefrom
the collecting system into the surgical bed. In most cases,
the ﬂuid collection resolves either spontaneously or after
placement of a ureteral stent or nephrostomy catheter. Less
commonly, urinary leakage persists and an urinoma forms
[20].
2.2.3. Infection
A ﬂuid collection in the surgical bed may become infected,
and an abscess may develop. With imaging techniques alone,
it may be diﬃcult to diﬀerentiate an infected ﬂuid collection
from an uninfected one. Moreover, as mentioned before, the
presence of air bubbles in a bioabsorbable haemostatic agent
mayfurthercomplicatetheinterpretationofimagingstudies.
However, patients with a postoperative abscess are likely to
manifest clinical symptoms and signs suggestive of infection;
in such cases, a needle aspiration is performed for laboratory
analysis, followed by drainage if necessary. In addition,
patients who have undergone a partial nephrectomy may
present with symptoms of pyelonephritis, which may appear4 Advances in Urology
Figure 4: Fibrosis. Axial post contrast T1 with fat saturation shows
a hipointense lesion on the lateral aspect of the left kidney that does
not enhance with gadolinium, revealing post surgical changes.
as a striated or heterogeneous nephrogram and may be
diﬃcult to diﬀerentiate from renal infarction on images
alone [20].
2.2.4. Complicationsduetotechnicalfactors
During partial nephrectomy, the liver or spleen may be
inadvertently lacerated or contused by surgical instruments
used to keep adjacent organs away from the surgical ﬁeld.
Such injuries may be detected with CT and MR imaging.
In addition, hernias may occur at the incision site and may
contain portions of the bowel or other abdominal organs
[26].
3. IMAGING OF LOCAL RECURRENCE
The most important risk factor for recurrence is the surgical
stage of renal cell carcinoma at the time of diagnosis,
being for large tumors a bigger incidence than for small
ones. However, size is not of prognostic value if capsule is
not invaded (13). Patients with positive nodes at surgery
relapse sooner, and factors like a high Fuhrman grade
on histopathology, and collecting duct carcinoma spindled
(sarcomatoid) tumor architecture also adversely inﬂuence
prognosis [27]. Recurrence must be diﬀerentiated from
postsurgical ﬁbrosis (Figure 4) and multifocality within the
kidney, probably more often seen since small renal tumors
aremanagedwithconservativesurgicaltechniques(Figure 5)
[13].
The possibility of local recurrence in the remaining
kidney is the main limitation of nephron-sparing surgery in
patients with renal-cell carcinoma. Local recurrence occurs
in about 5% of patients, and has been related to cancer
multifocality, incomplete resection of the primary tumor,
positivesurgicalmargins,orregionallymphnodemetastasis.
Some authors reported that the type of surgical intervention
(enucleation, enucleoresection and resection) does not aﬀect
the frequency of tumor local recurrence [28].
Recurrence usually occurs within the ﬁrst ﬁve years
after surgery, but late recurrence has been related to renal
cancer and long-term followup after a nephrectomy is
(a)
F
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Figure 5: Local recurrence. (a) Axial contrast enhanced CT scan
showing the postsurgical changes on the right lumbar fosse with
removal of the kidney and migration of the right colon to the
nephrectomy fosse. Note the second small renal lesion on the
anterior pole of the left kidney, probably due to multifocality that
was not advertised on the previous studies of the patient (arrow).
(b) A soft tissue mass on the medial aspect of the left kidney at the
site of the previous enucleation resection with enhancing nodules
around the kidney and adjacent to the psoas. (c) Enhanced nodules
adjacent to the diaphragm muscle (arrows).
mandatory for patients with perinephric invasion of a renal
cell carcinoma due to the risk of renal fosse recurrence [29].
Followup of these patients is usually made by CT but also
MRI for selected cases, as mentioned in the previous article
and, in both techniques, arterial phase scanning is essential
for maximizing lesion conspicuity, followed by a portal
venous phase. Owing to the increased risk of these patients
for additional renal primary carcinomas, the renal fosse and
remaining kidney must be carefully evaluated looking for a
recurrence.J. Santos et al. 5
3.1. Localrecurrenceinrenalfosseafternefrectomy
Recurrent cancer after nephron-sparing surgery can be
suggested when an enhancing nodule develops in the wedge-
shaped partial nephrectomy defect. After radical nephrec-
tomy at imaging, retroperitoneal anatomy is signiﬁcantly
altered after surgical removal of the kidney. Small bowel,
spleen, pancreas, and colon may migrate into the nephrec-
tomy fosse [30]( Figure 5(a)).
At partial nephrectomy if an adequate margin is not
obtained and surgical excision is incomplete, the growth of
any remaining neoplastic cells at the resection site over time
may result in tumor recurrence in the surgical bed. Even if a
tumor is completely excised, it may recur if tumor cells are
spilled into the surgical ﬁeld at the time of resection.
Alternatively, in a patient with multiple foci of disease,
an apparent tumor recurrence may actually be an additional
preexistent renal cell carcinoma that either was not depicted
atpreoperativeimagingstudiesorwasnotidentiﬁedintraop-
eratively [23]. The surgical ﬁeld of view during laparoscopic
partial nephrectomy is limited, and the surgeon can see only
a small portion of the kidney. This limitation may lead to
a failure to identify a speciﬁc small renal tumor if there is
more than one small lesion in the vicinity. Unless previous
imaging studies are carefully reviewed, the latter then might
be misidentiﬁed as a recurrent lesion.
The radiologic presentation of a recurrent renal carci-
noma after surgery appears as an enhancingmass in the
surgical site. The recurrence often involves the quadratus
lumborum and psoas muscles andcan displace or invade
nearby structures, even the spine. The cephalic extent may
reach the adrenal bed or may involve the ipsilateral adrenal
gland if the latter was spared at the time of nephrectomy
[31].
Moreover, as mentioned earlier, bioabsorbable haemo-
static agents may be seen as pseudotumor, so, a close
followup examination is required to see the evolution.
3.2. Localrecurrenceandresidualdiseaseafter
thermalablation
Early detection of a recurrence following initial treatment is
mandatory for any surveillance protocol, and it is essential
to review the preablation and ablation images for a good
interpretation of followup images. Imaging must be carefully
evaluatedtodeterminetheinitialtumorsize,tumorlocation,
and electrode placement in an eﬀort to predictare as that are
likely to demonstrate recurrence. Eccentric electrodeplace-
ment within a mass is likely to result in residual disease
at the tumor margin farthest from the ablation device tip.
Occasionally, a new tumor focus may develop.
As with local recurrence, residual tumor is suggested
when enhancing nodules or crescents areas noted in the
vicinity of the treated tumor on contrast enhanced CT
or MR images. Furthermore, gadolinium-enhanced fat-
suppressed T1-weighted subtraction MR images are helpful
in demonstrating subtle areas of enhancement by elimi-
nating the high signal intensity often present within the
tumor on unsubtracted images. Because the ablation zone
following RF ablation typically has low signal intensity
on T2-weighted MR images, a new or enlarging focus of
hyperintensity on these images may also be a sign of viable
tumor.
Ablated tumors remain stable in size or involute over
time on followup images. Therefore, an increase in tumor
sizeaftertheacutepostablationchangeshaveresolvedshould
raiseconcernfortumorrecurrence,aswellaswithintherenal
vein and inferior vena cava, even in the electrode insertion
site [30].
4. FOLLOWUP IMAGING AFTER RADIOFREQUENCY
ABLATION OF SRM
There has been a clear increase in the incidence of RCC
during the past 10 years, as a result of an increased rate of
incidental detection of renal neoplasm. It has been reported
that radiofrequency ablation can completely destroy renal
cancers, while transmitting minimal collateral damage to
surrounding renal parenchyma [32].
Radiofrequency ablation is a safe eﬀective treatment for
small renal-cell carcinoma (RCC) in selected patients who
are not good operative candidates. Small size and noncentral
location are favorable tumor characteristics (large tumors
can sometimes be successfully treated but could result in an
increased risk of residual RCC). After ablation, computed
tomography or magnetic resonance imaging is used to
conﬁrm complete eradication or the presence of residual
unablated tumor. When the appearance of the ablated tumor
deviates from expected ﬁndings, percutaneous biopsy is
necessary to further evaluate the ablation zone [33].
4.1. Imagingfollowup
All patients must undergo contrast-enhanced imaging (MRI
or CT) before radiofrequency ablation as a baseline com-
parison for subsequent imaging after ablation (initial tumor
control).
4.1.1. CTimaging
CT scan of the kidney must be obtained immediately after
the ablation session to assess tumor destruction. Normal
tissue shows enhancement, with no enhancement in treated
area, which encompasses tumor. Small gas bubbles are seen
in area of treatment, this is an expected ﬁnding resulting
from tissue boiling during ablation [34]. After ablation an
initial CT scan, imaging followup without and with contrast
agent must be performed after 1 month, 3 months, and 6
months and subsequent followup will depend on the clinical
condition of the patient and the comorbid conditions,
generally at 6 to 12 month interval. Enhancement of any
portion of the tumor must be considered residual viable
tumor, and the absence of enhancement as no evidence
of disease (complete necrosis and thus completely ablated
tumor). Images must also be reviewed for the presence of
any new metastatic disease or new renal cell carcinomas
[34, 35].6 Advances in Urology
4.1.2. MRimaging
A considerable number of patients of eligible patients
cannot receive contrast agents that contain iodine because
of preexisting impaired renal function or severe contrast
material allergies. These patients are usually referred for
contrast enhanced magnetic resonance (MR) imaging of the
kidney. As in CT imaging, followup MR imaging must be
performed in all patients immediately after the completion
oftheRFablation.AtT2-weightedfastSEimagesperformed,
the ablation zone, in all cases appear as a round or ovoid
hypointense region that replaces the intermediate or high
signal intensity tumor seen on the preablation image. The
hypointense thermal ablation zone is surrounded by a bright
rim with a well-deﬁned outer border. Thin rim enhancement
is noted in all contrast-enhanced MR images [36].
Followup MR imaging must be performed every 3
months during the ﬁrst year after ablation and every 6
months thereafter.
Tumor recurrence is deﬁned as the appearance of
hyperintense soft-tissue signal within the ablation zone or
along its margin on T2-weighted or STIR MR images or as
areas of abnormal contrast enhancement within the treated
region on the postcontrast images [37].
5. FOLLOWUP CRYOSURGYCAL ABLATION OF SRM
Concomitantly with the change in presentation of renal
masses there is a paradigm shift in the management of
localized small renal lesions. Minimally invasive options
such as cryoablation have emerged as an alternative surgical
option for selected patients. The potential complications of
nephron-sparing kidney surgery make renal cryoablation an
appealing option in high-risk surgical populations.
Cryoablationrequiresreal-timemonitoringoftheiceball
by ultrasound, CT, or magnetic resonance imaging (MRI),to
ensure that the tumour is completely frozen and to minimize
injury to the surrounding healthy tissue. However, it is
preferabletousetheMRimagingguidancetomonitorinreal
time so that the entire circumference of the treatment eﬀects
can be viewed during the procedure.
The MR imaging protocol is limited to the abdomen
and included: transverse T2-weighted, transverse T1-
weighted sequences, and transverse fat-suppressed T1-
weighted sequences before and four phases after the intra-
venous administration of contrast medium.
The purpose of the cryotherapy is not the excision of
the tumor, but their necrosis “in situ.” The eﬀects of renal
cryoabation on the kidney have been studied in animal
models [38].
The acute histologic changes are rapid coagulation
necrosis and a sharp zone of transition within the normal
kidney. A peripheral zone of incomplete necrosis surrounds
the area of necrosis. Over time, resorption of cellular debris
and ﬁbrosis lead to shrinkage of the cryolesion.
Given that the renal lesions are treated “in situ,” a
rigourous followup is required, usually with MR. Data form
long-term followup examinations are crucial to asses the
usefulness of cryotherapy and detecting tumor recurrence.
MR imaging and the same protocol used prior to the
treatment areperformedalsoat 24–48 hours aftertreatment,
for assessment of complications (bleeding or urinoma).
Remer and coworkers [39] reported several characteristic
ﬁndings in serial MR scans performed on the ﬁrst day,
1 month, 3 months, 6 months, and 12 months after
renal cryoablation. MR images are also compared with
the pretreatment MR images, to determine the amount of
cryonecrosis, deﬁned as tissue that no longer appeared to be
enhanced by intravenous contrast material.
The signal intensities of cryolesions on T1-and T2-
weighted images were somewhat variable. Lesions were
generally isointense on T1-weighted images and iso-or
hypointense on T2. The borders of cryolesions were well
depicted on T2-weighted images because of the relative
hypointensity of the lesion compared with normal renal
parenchyma.
In patients without evidence of tumor recurrence, all
cryolesions showed a dramatic progressive decrease in size
over time (63% and 94% at 1 month and 1 year, resp.). Some
cryolesions had a peripheral hypervascularized rim on T1-
weighted gadolinium enhanced images. This was seen in up
to 50% of lesions imaged within the ﬁrst 3 months after
ablation, but was present in just 10% of lesions at 12 months.
Initial rim enhancement has been reported in liver ablation
cases and has been attributed to the inﬂammatory response.
Anyincreaseinsizeofacryolesionshouldbeviewedwith
suspicion.
Although MR is the most studied method of monitoring
cryolesions,CThasalsobeenevaluated[40].Thecryolesions
onfollowupCTshowednoevidenceofenhancementandthe
tumor demonstrate stable size or decease in size.
APPENDIX
THE BOSNIAK RENAL CYST CLASSIFICATION SYSTEM
CategoryI
A benign simple cyst with a hairline-thin wall that does
not contain septa, calciﬁcations, or solid components: it
measures water density and does not enhance with contrast
material.
CategoryII
A benign cyst that may contain a few hairline-thin septa:
ﬁne calciﬁcation or a short segment of slightly thickened
calciﬁcation may be present in the wall or septa. Uniformly
high-attenuationlesions(<3cm)thataresharplymarginated
and do not enhance are included in this group.
CategoryIIF
These cysts may contain an increased number of hairline-
thin septa. Minimal enhancement of a hairline-thin smooth
septum or wall can be seen, and there may be minimal
thickening of the septa or wall. The cyst may contain
calciﬁcation that may be thick and nodular, but no contrastJ. Santos et al. 7
enhancement is present. There are no enhancing soft-
tissue components. Totally intrarenal nonenhancing high-
attenuation renal lesions that are 3cm or larger are also
included in this category. These lesions are generally well
marginated.
CategoryIII
These lesions are indeterminate cystic masses that have
thickened irregular walls or septa in which enhancement can
be seen.
CategoryIV
These lesions are clearly malignant cystic masses that not
only have all the characteristics of category III lesions, but
also contain enhancing soft-tissue components adjacent to
but independent of the wall or septa.
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